Bris­tol-My­ers and Seat­tle Ge­net­ics move a promis­ing flag­ship com­bo in­to PhI­II

Late last year in­ves­ti­ga­tors for Bris­tol-My­ers Squibb $BMY and Seat­tle Ge­net­ics $SGEN turned up at ASH with some stel­lar pi­lot da­ta from a Phase I/II com­bi­na­tion study match­ing Op­di­vo with Ad­cetris. In ad­di­tion to a 90% ob­jec­tive re­sponse rate in a small group of pa­tients, the team al­so tracked a 62% com­plete re­sponse rate among treat­ment-re­sis­tant pa­tients for clas­si­cal Hodgkin lym­phoma.

Now the part­ners want to see if they can get sim­i­lar re­sults in a piv­otal Phase III matchup.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER